The cagrilintide peptide is Novo Nordisk’s long-acting amylin receptor agonist that has produced some of the most significant weight loss data in metabolic research history — particularly in combination with semaglutide as CagriSema, which achieved 20.4% body weight reduction in the REDEFINE 1 Phase 3 trial (published in the New England Journal of Medicine) and has been submitted to the FDA for approval. The cagrilintide peptide represents a genuinely new mechanism of action in the metabolic peptide landscape: amylin receptor agonism, distinct from the GLP-1, GIP, and glucagon receptor pathways that compounds like Retatrutide and Tirzepatide target.

PSPeptides now offers research-grade cagrilintide at 99%+ HPLC-verified purity with batch-specific COAs, free shipping, and same-day processing including Sundays. This guide covers the cagrilintide peptide’s unique amylin mechanism, the landmark clinical trial data, FDA regulatory status, dosing protocols, and how it compares to other metabolic peptides in the PSPeptides catalog.

How the Cagrilintide Peptide Works: The Amylin Mechanism

The cagrilintide peptide is a long-acting analog of amylin (islet amyloid polypeptide) — a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells. Amylin naturally regulates satiety, gastric emptying, and post-meal glucose levels through receptors in the area postrema and hypothalamus. The cagrilintide peptide mimics and extends amylin’s actions with a half-life that supports once-weekly dosing.

This amylin mechanism is what makes the cagrilintide peptide genuinely novel in the metabolic peptide landscape. Semaglutide works through GLP-1 receptors. Tirzepatide works through GIP and GLP-1 receptors. Retatrutide works through GIP, GLP-1, and glucagon receptors. The cagrilintide peptide works through an entirely different receptor system — amylin receptors — which is why combining it with semaglutide (as CagriSema) produces additive weight loss beyond what either compound achieves alone.

CagriSema: The Landmark Clinical Trial Data

The cagrilintide peptide’s most impressive data comes from its combination with semaglutide as CagriSema. The landmark trials:

The REDEFINE 1 data — 20.4% weight loss at 68 weeks with 3,417 participants — published in the New England Journal of Medicine represents a landmark result. While Retatrutide’s TRIUMPH-1 achieved 28.3% through triple-agonist mechanisms, the cagrilintide peptide’s amylin pathway provides a complementary mechanism that could theoretically be combined with triple-agonist compounds for even greater effects. PubMed indexes the cagrilintide clinical trial publications.

FDA Regulatory Status of Cagrilintide in 2026

Novo Nordisk submitted a New Drug Application (NDA) for CagriSema (cagrilintide + semaglutide) to the FDA in December 2025 for weight management in adults with obesity or overweight. The FDA decision is anticipated in late 2026. Additionally, the REIMAGINE program is generating data for CagriSema in type 2 diabetes, and Novo Nordisk has indicated plans to discuss regulatory pathways for this indication following REIMAGINE 1 and 2 results. Cagrilintide as a standalone monotherapy is being evaluated in the separate RENEW Phase 3 program, but no monotherapy NDA has been filed. The FDA peptide reclassification guide covers the broader 2026 regulatory landscape.

Cagrilintide Peptide vs Other Metabolic Compounds

The cagrilintide peptide’s amylin mechanism provides a genuinely novel pathway — not a variation of incretin signaling but a fundamentally different receptor system. For researchers studying metabolic pathways, this makes the cagrilintide peptide an essential research tool alongside the GLP-1 and GIP agonists already in the PSPeptides catalog. The weight loss peptide guide and triple comparison guide cover the broader metabolic landscape. Researchers can explore all metabolic peptides at PSPeptides. Wikipedia covers cagrilintide’s pharmacology.

Understanding Amylin Biology and Receptor Signaling

To understand the cagrilintide peptide’s mechanism, researchers must understand the biology of amylin — the endogenous hormone that cagrilintide mimics. Amylin (islet amyloid polypeptide, IAPP) is a 37-amino-acid peptide co-secreted with insulin from pancreatic beta cells in response to nutrient intake. Published research documents amylin’s effects on three key metabolic processes: satiety signaling through the area postrema (reducing meal size), gastric emptying deceleration (prolonging nutrient absorption), and post-prandial glucagon suppression (improving glucose control).

The cagrilintide peptide extends these natural amylin actions with structural modifications that produce a dramatically longer half-life — supporting once-weekly dosing compared to native amylin’s half-life of approximately 13 minutes. This pharmacokinetic engineering is what makes it viable as a research tool: sustained amylin receptor activation throughout the dosing interval, rather than the brief, meal-associated pulses of natural amylin.

The CagriSema Synergy: How Amylin Amplifies GLP-1 Effects

The cagrilintide peptide’s most impressive data comes from its combination with semaglutide as CagriSema. The synergy works because amylin and GLP-1 regulate satiety through different neural pathways that converge in the hypothalamus. The cagrilintide peptide activates amylin receptors in the area postrema and nucleus tractus solitarius. Semaglutide activates GLP-1 receptors in the hypothalamic arcuate nucleus. The combined activation of both pathways produces greater appetite reduction and metabolic improvement than either pathway alone — a principle Nature Metabolism research (2026) has elucidated through cross-species dorsal vagal complex mapping.

The REDEFINE 1 data (20.4% weight loss with CagriSema vs 15.7% with semaglutide alone vs 8.1% with cagrilintide alone) quantifies this synergy: the combination exceeds the sum of individual components, confirming true pharmacological synergy rather than simple additivity. For metabolic researchers, the cagrilintide peptide provides the amylin pathway component of this synergistic system.

Research Protocol Considerations for Cagrilintide

The cagrilintide peptide is administered subcutaneously once weekly based on the clinical trial protocols. Published dosing from the REDEFINE program uses 2.4mg as the target maintenance dose, reached through a dose-escalation schedule. The free PSPeptides reconstitution calculator at pspeptides.com/peptide-calculator supports preparation for any cagrilintide peptide dose with visual syringe output.

Storage of the reconstituted compound follows standard protocols: 2-8°C, protected from light, used within the bacteriostatic water preservation window (28 days). Bacteriostatic water ($19.99) is available alongside cagrilintide at PSPeptides in a single free-shipping checkout. The reconstitution guide covers preparation technique.

The Complete PSPeptides Metabolic Research Catalog

Cagrilintide joins the most comprehensive metabolic research lineup available from any single vendor. Retatrutide (from $39.99) — triple GIP/GLP-1/glucagon agonist, 28.3% TRIUMPH-1 weight loss. Tirzepatide (from $54.99) — dual GIP/GLP-1 agonist, 20.9% SURMOUNT-1. AOD-9604 ($39.99) — hGH fragment lipolysis. MOTS-C (from $69.99) — mitochondrial fat oxidation. Tesamorelin (from $59.99) — FDA-approved GHRH analog. Together with cagrilintide (amylin pathway), PSPeptides provides research tools targeting every major metabolic receptor system documented in published weight loss research.

The PSPeptides Quality and Support Standard

PSPeptides provides research-grade peptides at 99%+ purity verified through third-party HPLC testing with batch-specific Certificates of Analysis from independent laboratories. US-based manufacturing under domestic regulatory oversight. Same-day processing seven days a week including Sundays. Free shipping on every domestic order. Free international shipping to 30+ countries on orders over $150. Zero processing fees on Affirm, Afterpay, Zelle, cards, Apple Pay, and Google Pay. 24/7 customer support via live chat, email at [email protected], and phone/text at (551) 284-2670.

The free reconstitution and dosage calculator at pspeptides.com/peptide-calculator provides visual syringe diagrams and video tutorials for accurate preparation of every compound. The 5-star rating from thousands of verified customers confirms consistent quality and service. Complete supplies — bacteriostatic water ($19.99), EasyTouch insulin syringes, and alcohol prep pads — ship alongside research peptides in a single free checkout. PSPeptides provides the complete research peptide experience: verified compounds, essential supplies, preparation tools, educational resources, and around-the-clock human support.

The REDEFINE Trial Program: Detailed Evidence Review

The cagrilintide peptide’s clinical evidence is anchored in the REDEFINE trial program — one of the largest metabolic peptide trial programs ever conducted. REDEFINE 1 (3,417 participants, obesity without T2D) is the pivotal trial that established CagriSema’s 20.4% weight loss at 68 weeks — published in the New England Journal of Medicine. REDEFINE 2 (1,206 participants, obesity with T2D) demonstrated 13.7% weight loss with significant HbA1c improvement. REDEFINE 4 was the head-to-head comparison of CagriSema versus tirzepatide, completed January 2026.

The REIMAGINE program expanded the cagrilintide peptide’s evidence base into type 2 diabetes specifically. REIMAGINE 2 (2,728 participants with T2D on metformin) demonstrated CagriSema’s superiority to semaglutide alone — achieving -1.91% HbA1c reduction and 14.2% weight loss at 68 weeks. Together, these trials represent over 8,000 participants across multiple metabolic populations — making cagrilintide one of the most extensively studied metabolic research compounds of the decade.

Why the Amylin Pathway Matters for Metabolic Research

The cagrilintide peptide’s amylin mechanism matters because it represents a genuinely new therapeutic axis for metabolic research. Every major weight loss compound in the past decade has targeted incretin receptors: semaglutide (GLP-1), tirzepatide (GIP + GLP-1), retatrutide (GIP + GLP-1 + glucagon). The cagrilintide peptide breaks this pattern by targeting amylin receptors — providing a metabolic research tool that operates through completely different neural and hormonal pathways.

This mechanistic novelty has two research implications. First, this compound allows researchers to study amylin-mediated metabolic regulation independently — understanding how amylin receptor activation affects satiety, gastric emptying, and glucose control without incretin pathway confounding. Second, its proven synergy with GLP-1 agonism (CagriSema data) suggests that amylin + incretin combination research may yield insights into multi-pathway metabolic intervention that single-pathway approaches cannot reveal. Buy cagrilintide at PSPeptides for amylin pathway research.

Cagrilintide in the Competitive Metabolic Research Landscape

Cagrilintide occupies a unique position in the metabolic research compound landscape. It is the ONLY research peptide targeting the amylin receptor system — every other major metabolic compound targets incretin (GLP-1, GIP) or glucagon receptors. This mechanistic exclusivity means the cagrilintide peptide provides a research tool that no other compound can substitute. Semaglutide, tirzepatide, and retatrutide all offer variations on incretin agonism. Only cagrilintide provides amylin pathway access for metabolic researchers.

This unique positioning is reinforced by the clinical validation: REDEFINE 1’s NEJM publication, the FDA NDA filing, and the 8,000+ trial participant evidence base. It is not a speculative research compound — it is a clinically validated mechanism backed by the most rigorous Phase 3 data any amylin analog has ever generated. Buy cagrilintide at PSPeptides with 99%+ purity, free shipping, and same-day processing.

Getting Started with Cagrilintide Research at PSPeptides

Starting cagrilintide research at PSPeptides: order cagrilintide with bacteriostatic water ($19.99), EasyTouch syringes, and alcohol prep pads. One checkout, free shipping, same-day processing. Use the free calculator for dose preparation. Cagrilintide joins PSPeptides’ metabolic catalog as the amylin pathway research tool that completes the most comprehensive weight loss peptide lineup available from any single vendor.

The Future of Metabolic Research: Amylin Pathway Science

Cagrilintide represents the next frontier of metabolic peptide research. With an FDA NDA filed for CagriSema (decision expected late 2026), Phase 3 data published in the NEJM, and over 8,000 trial participants across multiple metabolic populations, cagrilintide has achieved a level of clinical validation that only a handful of research peptides can claim. The amylin mechanism it represents is genuinely new — not another variation on incretin signaling, but a different receptor system that complements existing GLP-1 and GIP research.

PSPeptides provides the research community with early access to this clinically validated mechanism. Cagrilintide at PSPeptides — 99%+ HPLC-verified purity, batch-specific COAs, free shipping, same-day processing, complete supplies in one checkout, and 24/7 support. For metabolic researchers who want to study the amylin pathway alongside the incretin compounds (Retatrutide, Tirzepatide) already in the PSPeptides catalog, cagrilintide provides the missing piece that completes the most comprehensive metabolic research toolkit available from any single vendor.

Its research significance extends beyond weight loss: amylin receptor biology intersects with glucose regulation, satiety neuroscience, gastric physiology, and the multi-pathway approach to metabolic intervention that defines the next generation of metabolic research. PSPeptides puts this cutting-edge research tool in researchers’ hands — today, with verified quality, at the speed and accessibility that important research demands.

Understanding this amylin analog is essential for researchers navigating this rapidly evolving field in 2026.

Safety and Tolerability Profile in Clinical Research

Published data from the REDEFINE trial program provides a well-characterized safety profile for cagrilintide and CagriSema across more than 8,000 research participants. Gastrointestinal events represent the most commonly reported adverse effects, consistent with the satiety-enhancing mechanism of action. In REDEFINE 1, nausea was reported in approximately 33% of CagriSema participants versus 7% in the placebo group. Vomiting occurred in 17% versus 4%, and diarrhea in 18% versus 11%. The majority of these events were mild to moderate in severity and decreased in frequency after the dose-escalation phase was complete.

Injection-site reactions were documented in a subset of participants, consistent with subcutaneous peptide administration generally. The REDEFINE 1 data showed injection-site reactions in approximately 8% of CagriSema participants — a rate comparable to other once-weekly subcutaneous metabolic peptides. Hypoglycemia risk was low in non-diabetic populations, with no clinically meaningful difference between CagriSema and placebo in REDEFINE 1 for fasting glucose levels in the absence of concomitant insulin or sulfonylurea use.

Discontinuation due to adverse events occurred in 9.2% of CagriSema participants in REDEFINE 1, compared to 2.9% in the placebo arm. These discontinuation rates are consistent with the broader GLP-1 compound class and primarily reflect gastrointestinal tolerability during the dose-escalation phase. REDEFINE 2 (obesity with type 2 diabetes) showed similar tolerability patterns, with 10.1% discontinuation in the CagriSema arm.

Heart rate increases — a known monitoring parameter with some incretin-class compounds — were evaluated across the REDEFINE program. Published REDEFINE 1 data reported mean heart rate increases of approximately +3 beats per minute in the CagriSema arm, a modest effect that researchers note is consistent with the GLP-1 component’s known pharmacology. The amylin receptor component (cagrilintide’s contribution) did not appear to independently modulate heart rate based on the RENEW monotherapy program’s interim data.

For research protocol design, published REDEFINE data supports careful dose-escalation as the primary tolerability management strategy. The clinical program used a standardized dose escalation schedule over 16 weeks to reach the 2.4mg target maintenance dose — a design feature that substantially improved tolerability compared to initiating at the maintenance dose. Researchers reviewing this safety data can access the complete REDEFINE 1 publication through PubMed’s indexed clinical trial database.

Frequently Asked Questions

What is the cagrilintide peptide?

Cagrilintide is a long-acting amylin analog by Novo Nordisk. Combined with semaglutide as CagriSema, it achieved 20.4% weight loss in the REDEFINE 1 Phase 3 trial published in the NEJM.

How is cagrilintide different from Retatrutide?

Cagrilintide targets amylin receptors — a completely different pathway from Retatrutide’s triple GIP/GLP-1/glucagon mechanism. PSPeptides carries both for comparative metabolic research.

Is cagrilintide FDA-approved?

Not yet. Novo Nordisk submitted the CagriSema NDA in December 2025. FDA decision is expected in late 2026. Cagrilintide is available for research use at PSPeptides.

Does PSPeptides sell cagrilintide?

Yes. Research-grade cagrilintide at 99%+ purity with batch-specific COAs. Free shipping, same-day processing, Affirm/Afterpay at zero fees.

All PSPeptides products are sold exclusively for research and laboratory use.